SCHEMBL149035

SCHEMBL149035

N#Cc1cc(-c2ccc(F)c(F)c2)ccc1Nc1ccc(C(=O)N2CCOCC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 3/20 0.53
JAK2 O60674 3/20 0.51
LMNA P02545 2/20 0.48
ERN1 O75460 1/20 0.48
EPHX2 P34913 2/20 0.47
TBK1 Q9UHD2 1/20 0.46
JAK1 P23458 1/20 0.45
JAK3 P52333 1/20 0.45
MAPK14 Q16539 1/20 0.44
LRRK2 Q5S007 2/20 0.43
PDE4B Q07343 1/20 0.43
CTSC P53634 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
PHGDH O43175 1/20 0.43
TTK P33981 1/20 0.42
KDM1A O60341 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27852018 0.87 TYK2 (0.55) TYK2JAK2LMNAEPHX2TBK1
SCHEMBL142118 0.86 TTK (0.51) TYK2JAK2TBK1LRRK2TTK
SCHEMBL141118 0.86 TYK2 (0.55) TYK2JAK2LMNAEPHX2TBK1
SCHEMBL144961 0.85 TYK2 (0.49) TYK2JAK2LMNAEPHX2TBK1
SCHEMBL142450 0.82 TYK2 (0.50) TYK2LMNAEPHX2LRRK2PHGDH
SCHEMBL140875 0.80 EPHX2 (0.57) TYK2JAK2LMNAEPHX2JAK1
SCHEMBL8167348 0.80 ERN1 (0.69) JAK2ERN1EPHX2PDE4BPHGDH
SCHEMBL27833935 0.80 TYK2 (0.55) TYK2LMNAEPHX2JAK3PHGDH
SCHEMBL144185 0.78 JAK2 (0.44) TYK2JAK2TBK1LRRK2CYP11B1
SCHEMBL141845 0.77 TYK2 (0.48) TYK2JAK2JAK1JAK3MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 TYK2 5/4885JAK2 1/4885LMNA 4273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.